Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - ipilimumab 5 mg/ml;   - concentrate for injection - 200 mg/40 ml - active: ipilimumab 5 mg/ml   excipient: hydrochloric acid mannitol nitrogen pentetic acid polysorbate 80 sodium chloride sodium hydroxide trometamol hydrochloride water for injection - yervoy, as monotherapy, is indicated for the treatment of patients with unresectable or metastatic melanoma in adults, 18 years of age or older. yervoy, in combination with opdivo (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic disease melanoma.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - ipilimumab 5 mg/ml;   - concentrate for injection - 50 mg/10 ml - active: ipilimumab 5 mg/ml   excipient: hydrochloric acid mannitol nitrogen pentetic acid polysorbate 80 sodium chloride sodium hydroxide trometamol hydrochloride water for injection - yervoy, as monotherapy, is indicated for the treatment of patients with unresectable or metastatic melanoma in adults, 18 years of age or older. yervoy, in combination with opdivo (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic disease melanoma.

Regne Unit - anglès - myHealthbox

bristol-myers squibb pharma eeig - nivolumab - concentrate for solution for infusion - 10 mg/ml - antineoplastic agents, monoclonal antibodies - as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults

Regne Unit - anglès - myHealthbox

bristol myers squibb pharmaceuticals ltd. - pravastatin sodium - tablets - 20 mg - serum lipid reducing agents/cholesterol and triglyceride reducers/hmg-coa reductase inhibitors - treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate; reduction of cardiovascular mortality and morbidity in patients with moderate or severe hypercholesterolaemia and at high risk of a first cardiovascular event, as an adjunct to diet: reduction of cardiovascular mortality and morbidity in patients with a history of myocardial infarction (mi) or unstable angina pectoris and with either normal or increased cholesterol levels, as an adjunct to correction of other risk factors; reduction of post transplantation hyperlipidaemia in patients receiving immunosuppressive therapy following solid organ transplantation

Regne Unit - anglès - myHealthbox

bristol myers squibb pharmaceuticals ltd. - pravastatin sodium - tablets - 40mg - serum lipid reducing agents/cholesterol and triglyceride reducers/hmg-coa reductase inhibitors - treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate; reduction of cardiovascular mortality and morbidity in patients with moderate or severe hypercholesterolaemia and at high risk of a first cardiovascular event, as an adjunct to diet; reduction of cardiovascular mortality and morbidity in patients with a history of myocardial infarction (mi) or unstable angina pectoris and with either normal or increased cholesterol levels, as an adjunct to correction of other risk factors; reduction of post transplantation hyperlipidaemia in patients receiving immunosuppressive therapy following solid organ transplantation.

Regne Unit - anglès - myHealthbox

bristol myers squibb pharmaceuticals ltd. - pravastatin sodium - tablets - 10mg - serum lipid reducing agents/cholesterol and triglyceride reducers/hmg-coa reductase inhibitors - treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate; reduction of cardiovascular mortality and morbidity in patients with moderate or severe hypercholesterolaemia and at high risk of a first cardiovascular event, as an adjunct to diet; reduction of cardiovascular mortality and morbidity in patients with a history of myocardial infarction (mi) or unstable angina pectoris and with either normal or increased cholesterol levels, as an adjunct to correction of other risk factors; reduction of post transplantation hyperlipidaemia in patients receiving immunosuppressive therapy following solid organ transplantation.

Israel - anglès - Ministry of Health

bristol, myers squibb (israel) limited, israel - ozanimod as hydrochloride - capsules - ozanimod as hydrochloride 0.23 mg - ozanimod - zeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features.zeposia is indicated for the treatment of moderately to severely active ulcerative colitis (uc) in adults.

Israel - anglès - Ministry of Health

bristol, myers squibb (israel) limited, israel - ozanimod as hydrochloride - capsules - ozanimod as hydrochloride 0.46 mg - ozanimod - zeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features.zeposia is indicated for the treatment of moderately to severely active ulcerative colitis (uc) in adults.

Israel - anglès - Ministry of Health

bristol, myers squibb (israel) limited, israel - ozanimod as hydrochloride - capsules - ozanimod as hydrochloride 0.92 mg - ozanimod - zeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features.zeposia is indicated for the treatment of moderately to severely active ulcerative colitis (uc) in adults.

Israel - anglès - Ministry of Health

bristol, myers squibb (israel) limited, israel - elotuzumab - powder for concentrate for solution for infusion - elotuzumab 300 mg/vial - elotuzumab - empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.empliciti is indicated in combination with pomalidomide and dexamethasone for the treatment ofadult patients with relapsed and refractory multiple myeloma who have received at least two priortherapies, including lenalidomide and a proteasome inhibitor, and have demonstrated diseaseprogression on the last therapy.